Krystal Biotech Inc. (KRYS)
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to loss of $0.67 per share a year ago.
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy
Krystal Biotech (KRYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows promise in aesthetics with positive phase 1 data, changing the treatment paradigm in the aesthetics market space. VYJUVEK, approved for DEB, saw a 55.3% revenue increase in Q2 2024, with potential European expansion pending MAA approval.
Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Stéphane Paquette - Vice President, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - Senior Vice President, Patient Access, Analytics and Operations Christine Wilson - Senior Vice President and Head, U.S. Sales and Marketing Kate Romano - Chief Accounting Officer Conference Call Participants Alec Stranahan - Bank of America Ritu Baral - TD Cowen Andrea Tan - Goldman Sachs John Boyle - William Blair Yigal Nochomovitz - Citi Gavin Clark Gartner - Evercore ISI Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Securities Operator Thank you for standing by. And welcome to Krystal Biotech's Second-Quarter 2024 Earnings Conference Call.
Krystal Biotech (KRYS) Upgraded to Buy: What Does It Mean for the Stock?
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to loss of $1.25 per share a year ago.
Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Krystal Biotech's Q1 2024 revenue increased to $45.25 million but fell short of analyst expectations of $47.37 million. Analysts expect Q2 earnings to be $65.49 million. Vyjuvek's patient adherence rate dropped slightly to 91% in Q1 from 96% in the previous quarter. Krystal's pipeline, beyond dermatological and aesthetic pursuits, is pretty speculative and pursuing highly contested indications.
Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
Krystal Biotech (KRYS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Earnings Estimates Moving Higher for Krystal Biotech (KRYS): Time to Buy?
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
